Table 97.
Human NK cell inhibitory and activating receptors
| Receptor | Ligand | CD56bright | CD56dim | |
|---|---|---|---|---|
| Activation | NKG2C (CD159a) | HLA-E | – | subsets |
| NKG2D (CD314) | MIC-A - MIC-B - ULBPs | All PB NK cells | ||
| KIR2DS1 (CD158h) | HLA-C2 | – | subsets | |
| KIR2DS2/3 (CD158j) | ??? | – | subsets | |
| KIR2DL4 (CD158d) | HLA-G | – | subsets | |
| KIR2DS4 (CD158i) | HLA-A*11 and some HLA-C | – | subsets | |
| KIR2DS5 (CD158f) | ??? | – | subsets | |
| KIR3DS1 (CD158e1) | HLA-Bw4, HLA-F | – | subsets | |
| NKp30 (CD337) | B7-H6 - BAG6/BAT3 | ++ | + | |
| NKp44 (CD336) | 21spe-MLL5, Nidogen 1 | On activated NK cells | ||
| NKp46 (CD335) | CFP (properdin), haemagglutinin, PfEMP1 | ++ | + | |
| NKp80 | AICL | + | + | |
| DNAM1 (CD226) | Nectin-2 (CD112), PVR (CD155) | + | + | |
| 2B4 (CD244) | CD48 | All PB NK cells | ||
| NTB-A (CD352) | NTB-A (CD352) | All PB NK cells | ||
| CRACC/CS1 (CD319) | CRACC/CS1 (CD319) | All PB NK cells | ||
| Tactile (CD96) | PVR (CD155) | All PB NK cells | ||
| FcγRIII (CD16) | IgG | −/+ | +/++ | |
| Inhibition | NKG2A/KLRD1 (CD159a/CD94) | HLA-E | + | subsets |
| KIR2DL1 (CD158a) | HLA-C2 | − | subsets | |
| KIR2DL2/3 (CD158b) | HLA-C1, few HLA-C2 | − | subsets | |
| KIR2DL4 (CD158d) | HLA-G | − | subsets | |
| KIR2DL5 (CD158f) | ??? | − | subsets | |
| KIR3DL1 (CD158e1) | HLA-A-Bw4 and HLA-B-Bw4 | − | subsets | |
| KIR3DL2 (CD158k) | HLA-A*03 and *11 | − | subsets | |
| ILT2/LIR-1 (CD85J) | Different MHC-I alles | − | subsets | |
| PD-1 (CD279) | PDL1 (CD274) and PDL2 (CD273) | − | subsets | |
| Siglec-7 (CD328) | Ganglioside DSGb5 | Most of PB NK cells | ||
| IRP60 (CD300a) | α-herpes virus Pseudorabide virus Phosphatidylserine Phosphatidylethnolamine | + | + | |
| TIGIT | PVR (CD155) | PB NK cells |